BrainStorm Gears Up for Phase IIIb NurOwn Trial Amidst ALS Malaise
It’s been a difficult year for the amyotrophic lateral sclerosis community. The hits have come hard and fast, with the withdrawal of Amylyx’s Relvyrio from the market and the mid-stage failure of Sanofi and Denali Therapeutics’ candidate. Against this …